bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Data from Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis
Authors: Yoon Harry H. , Shi Qian , Heying Erica N. , Muranyi Andrea , Bredno Joerg , Ough Faith , Djalilvand Azita , Clements June , Bowermaster Rebecca , Liu Wen-Wei , Barnes Michael , Alberts Steven R. , Shanmugam Kandavel , Sinicrope Frank A.
Published: April 2023

Figure S1 Study flow of N0147 patient tumor samples Figure S2 Heterogeneity of lymphocytic infiltrate between patients in mismatch repair deficient (dMMR) and proficient (pMMR) tumors. The distribution of T-cell densities (score 0-100) are shown as follows: (a) CD3+ in the core of the tumor, (b) CD8+ at the invasive margin, (c) CD8+ in the core of the tumor. For each T-cell subtype, density of tumor infiltration was higher in dMMR vs pMMR tumors (each p <.001).
Supplementary Data 4 from A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
Authors: Ghobrial Irene M. , Liu Chia-Jen , Redd Robert A. , Perez Raymond P. , Baz Rachid , Zavidij Oksana , Sklavenitis-Pistofidis Romanos , Richardson Paul G. , Anderson Kenneth C. , Laubach Jacob , Henrick Patrick , Savell Alexandra , Reyes Kaitlen , Hornburg Kalvis , Chuma Stacey , Sabbatini Peter , Robbins Michael D. , Becker Pamela S.
Published: April 2023

This figure shows Absolute cell numbers in the peripheral blood of patients receiving 10mg/kg ulocuplumab (absolute count, cells/uL).
Supplementary Data 1 from A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
Authors: Ghobrial Irene M. , Liu Chia-Jen , Redd Robert A. , Perez Raymond P. , Baz Rachid , Zavidij Oksana , Sklavenitis-Pistofidis Romanos , Richardson Paul G. , Anderson Kenneth C. , Laubach Jacob , Henrick Patrick , Savell Alexandra , Reyes Kaitlen , Hornburg Kalvis , Chuma Stacey , Sabbatini Peter , Robbins Michael D. , Becker Pamela S.
Published: April 2023

This figure presents a consort diagram showing (A) the dose-escalation scheme for BMS-936564 (ulocuplumab), (B) the dose-expansion scheme, including Arms A & B, of the study and (C) Number of patients at each dose level in the phase I and II studies and in arms A and B.
Figure S4 from Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer
Authors: Flores-Morales Amilcar , Bergmann Tobias B. , Lavallee Charlotte , Batth Tanveer S. , Lin Dong , Lerdrup Mads , Friis Stine , Bartels Anette , Kristensen Gitte , Krzyzanowska Agnieszka , Xue Hui , Fazli Ladan , Hansen Klaus H. , Røder Martin A. , Brasso Klaus , Moreira José M. , Bjartell Anders , Wang Yuzhuo , Olsen Jesper V. , Collins Colin C. , Iglesias-Gato Diego
Published: April 2023

Figure S4
Figure S2 from Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer
Authors: Flores-Morales Amilcar , Bergmann Tobias B. , Lavallee Charlotte , Batth Tanveer S. , Lin Dong , Lerdrup Mads , Friis Stine , Bartels Anette , Kristensen Gitte , Krzyzanowska Agnieszka , Xue Hui , Fazli Ladan , Hansen Klaus H. , Røder Martin A. , Brasso Klaus , Moreira José M. , Bjartell Anders , Wang Yuzhuo , Olsen Jesper V. , Collins Colin C. , Iglesias-Gato Diego
Published: April 2023

Figure S2
Supplementary Data from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore
Authors: Steenbruggen Tessa G. , van Seijen Maartje , Janssen Liselore M. , van Ramshorst Mette S. , van Werkhoven Erik , Vrancken Peeters Marie-Jeanne T.D.F. , Wesseling Jelle , Lips Esther H. , Sonke Gabe S.
Published: April 2023

Supplementary data to Steenbruggen TG, van Seijen M, Janssen LM, van Ramshorst MS, van Werkhoven E, Vrancken Peeters MJTDF, et al. Prognostic value of residual disease after neoadjuvant therapy in HER2-positive breast cancer evaluated by Residual Cancer Burden, Neoadjuvant Response Index & Neo-Bioscore. Table S1, Table S2, Table S3, Table S4, Text and legend Figure S1
Supplemental Figure S7 from Smoothened Promotes Glioblastoma Radiation Resistance Via Activating USP3-Mediated Claspin Deubiquitination
Authors: Tu Yiming , Chen Zhenyao , Zhao Pengzhan , Sun Guangchi , Bao Zhongyuan , Chao Honglu , Fan Liang , Li Chong , You Yongping , Qu Yan , Chen Yun , Ji Jing
Published: April 2023

Supplemental Figure S7
Supplementary Table 6 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
Authors: Keung Emily Z. , Burgess Melissa , Salazar Ruth , Parra Edwin R. , Rodrigues-Canales Jaime , Bolejack Vanessa , Van Tine Brian A. , Schuetze Scott M. , Attia Steven , Riedel Richard F. , Hu James , Okuno Scott H. , Priebat Dennis A. , Movva Sujana , Davis Lara E. , Reed Damon R. , Reuben Alexandre , Roland Christina L. , Reinke Denise , Lazar Alexander J. , Wang Wei-Lien , Wargo Jennifer A. , Tawbi Hussein A.
Published: April 2023

Comparison of tumor PD-L1 expression and tumor immune infiltrate between baseline biopsies and at 8 weeks on treatment (bone only)
Supplemental Figure S3 from Smoothened Promotes Glioblastoma Radiation Resistance Via Activating USP3-Mediated Claspin Deubiquitination
Authors: Tu Yiming , Chen Zhenyao , Zhao Pengzhan , Sun Guangchi , Bao Zhongyuan , Chao Honglu , Fan Liang , Li Chong , You Yongping , Qu Yan , Chen Yun , Ji Jing
Published: April 2023

Supplemental Figure S3
Supplementary Table 1 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
Authors: Keung Emily Z. , Burgess Melissa , Salazar Ruth , Parra Edwin R. , Rodrigues-Canales Jaime , Bolejack Vanessa , Van Tine Brian A. , Schuetze Scott M. , Attia Steven , Riedel Richard F. , Hu James , Okuno Scott H. , Priebat Dennis A. , Movva Sujana , Davis Lara E. , Reed Damon R. , Reuben Alexandre , Roland Christina L. , Reinke Denise , Lazar Alexander J. , Wang Wei-Lien , Wargo Jennifer A. , Tawbi Hussein A.
Published: April 2023

Demographic and clinical characteristics of 84 eligible, treated patients
Table S3 from Human Breast Cancer Xenograft Model Implicates Peroxisome Proliferator–activated Receptor Signaling as Driver of Cancer-induced Muscle Fatigue
Authors: Wilson Hannah E. , Rhodes Kacey K. , Rodriguez Daniel , Chahal Ikttesh , Stanton David A. , Bohlen Joseph , Davis Mary , Infante Aniello M. , Hazard-Jenkins Hannah , Klinke David J. , Pugacheva Elena N. , Pistilli Emidio E.
Published: April 2023

Table S3 shows data for correlational analyses between muscle contractile parameters and STAT activation
Supplementary Figure 3 from Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma
Authors: Tan Yinfei , Sementino Eleonora , Cheung Mitchell , Peri Suraj , Menges Craig W. , Kukuyan Anna-Mariya , Zhang Ting , Khazak Vladimir , Fox Lauren A. , Ross Eric A. , Ramanathan Suresh , Jhanwar Suresh C. , Flores Raja M. , Balachandran Siddharth , Testa Joseph R.
Published: April 2023

Immunoblot analysis of primary pleural MM specimens and PDXs from primary pleural MM specimens. A, Western blotting illustrating frequent absence of detectable protein expression of tumor suppressors p16INK4A, p14ARF, and p15INK4B in 27 primary MM specimens. NMC 1115 and NMC 2916 are normal mesothelial cell lines, used controls. B, Very low or undetectable expression of RIPK3 and RIPK1 proteins in 4 PDXs from primary MM patients, and expression of tumor suppressors BAP1 and NF2 (left panel) and p16INK4A, p14ARF, and p15INK4B (right panel). Expression of MLKL as well as MM-related tumor suppressors BAP1 and NF2 are included for comparison. Abbreviations: NMC, normal mesothelial cells; PDX, patient derived xenografts.
Supplementary Data from BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells
Authors: Atay Cigdem , Kwak Taekyoung , Lavilla-Alonso Sergio , Donthireddy Laxminarasimha , Richards Allison , Moberg Valerie , Pilon-Thomas Shari , Schell Michael , Messina Jane L. , Rebecca Vito W. , Xiao Min , Tan Jiufeng , Zhang Gao , Weber Jeffrey S. , Herlyn Meenhard , Sarnaik Amod A. , Gabrilovich Dmitry I.
Published: April 2023

Supplemental Figure 1. Temporal regulation and the effect of combination of B-raf inhibitor on M6PR expression. Supplemental Figure 2. Effect of combination of B-raf and MEK inhibitors on M6PR expression. Supplemental Figure 3. WM35 cells resistant to PLX4720. Supplemental Figure 4. Effect of M6PR overexpression and deletion on melanoma cell sensitivity to PLX4720 in MTT test. Supplemental Figure 5. Expression of surface molecules on melanoma cells with manipulated expression of M6PR. Supplemental Table 1 Clinical characteristics of patients enrolled to the study Supplemental Table 2. Grade 3+ Adverse Events in treated patients
Figure S4 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
Authors: Chakraborty Goutam , Armenia Joshua , Mazzu Ying Z. , Nandakumar Subhiksha , Stopsack Konrad H. , Atiq Mohammad O. , Komura Kazumasa , Jehane Lina , Hirani Rahim , Chadalavada Kalyani , Yoshikawa Yuki , Khan Nabeela A. , Chen Yu , Abida Wassim , Mucci Lorelei A. , Lee Gwo-Shu Mary , Nanjangud Gouri J. , Kantoff Philip W.
Published: April 2023

Supplementary Figure S4
Figure S2 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
Authors: Chakraborty Goutam , Armenia Joshua , Mazzu Ying Z. , Nandakumar Subhiksha , Stopsack Konrad H. , Atiq Mohammad O. , Komura Kazumasa , Jehane Lina , Hirani Rahim , Chadalavada Kalyani , Yoshikawa Yuki , Khan Nabeela A. , Chen Yu , Abida Wassim , Mucci Lorelei A. , Lee Gwo-Shu Mary , Nanjangud Gouri J. , Kantoff Philip W.
Published: April 2023

Supplementary Figure S2
Figure S3 from Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
Authors: Recondo Gonzalo , Mezquita Laura , Facchinetti Francesco , Planchard David , Gazzah Anas , Bigot Ludovic , Rizvi Ahsan Z. , Frias Rosa L. , Thiery Jean Paul , Scoazec Jean-Yves , Sourisseau Tony , Howarth Karen , Deas Olivier , Samofalova Dariia , Galissant Justine , Tesson Pauline , Braye Floriane , Naltet Charles , Lavaud Pernelle , Mahjoubi Linda , Abou Lovergne Aurélie , Vassal Gilles , Bahleda Rastilav , Hollebecque Antoine , Nicotra Claudio , Ngo-Camus Maud , Michiels Stefan , Lacroix Ludovic , Richon Catherine , Auger Nathalie , De Baere Thierry , Tselikas Lambros , Solary Eric , Angevin Eric , Eggermont Alexander M. , Andre Fabrice , Massard Christophe , Olaussen Ken A. , Soria Jean-Charles , Besse Benjamin , Friboulet Luc
Published: April 2023

Supplementary Figure 3: NF2 deleterious mutations and sensitivity to lorlatinib (corresponding to main Figure 4).
Figure S1 from Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
Authors: Recondo Gonzalo , Mezquita Laura , Facchinetti Francesco , Planchard David , Gazzah Anas , Bigot Ludovic , Rizvi Ahsan Z. , Frias Rosa L. , Thiery Jean Paul , Scoazec Jean-Yves , Sourisseau Tony , Howarth Karen , Deas Olivier , Samofalova Dariia , Galissant Justine , Tesson Pauline , Braye Floriane , Naltet Charles , Lavaud Pernelle , Mahjoubi Linda , Abou Lovergne Aurélie , Vassal Gilles , Bahleda Rastilav , Hollebecque Antoine , Nicotra Claudio , Ngo-Camus Maud , Michiels Stefan , Lacroix Ludovic , Richon Catherine , Auger Nathalie , De Baere Thierry , Tselikas Lambros , Solary Eric , Angevin Eric , Eggermont Alexander M. , Andre Fabrice , Massard Christophe , Olaussen Ken A. , Soria Jean-Charles , Besse Benjamin , Friboulet Luc
Published: April 2023

Supplementary Figure 1: EMT mediated lorlatinib resistance (corresponding to main Figure 2).
Supplemental Figure 2 from Racial Differences in the Association Between Luminal Master Regulator Gene Expression Levels and Breast Cancer Survival
Authors: Byun Jung S. , Singhal Sandeep K. , Park Samson , Yi Dae Ik , Yan Tingfen , Caban Ambar , Jones Alana , Mukhopadhyay Partha , Gil Sara M. , Hewitt Stephen M. , Newman Lisa , Davis Melissa B. , Jenkins Brittany D. , Sepulveda Jorge L. , De Siervi Adriana , Nápoles Anna María , Vohra Nasreen A. , Gardner Kevin
Published: April 2023

Supplemental Figure 2 Subtype specific breast cancer survival comparisons.
Figure S9 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
Authors: Ritch Elie , Fu Simon Y.F. , Herberts Cameron , Wang Gang , Warner Evan W. , Schönlau Elena , Taavitsainen Sinja , Murtha Andrew J. , Vandekerkhove Gillian , Beja Kevin , Loktionova Yulia , Khalaf Daniel , Fazli Ladan , Kushnir Igal , Ferrario Cristiano , Hotte Sebastien , Annala Matti , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure 9. Comparison of tumor mutation burden between primary tissue and cfDNA collections.
Figure S12 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
Authors: Ritch Elie , Fu Simon Y.F. , Herberts Cameron , Wang Gang , Warner Evan W. , Schönlau Elena , Taavitsainen Sinja , Murtha Andrew J. , Vandekerkhove Gillian , Beja Kevin , Loktionova Yulia , Khalaf Daniel , Fazli Ladan , Kushnir Igal , Ferrario Cristiano , Hotte Sebastien , Annala Matti , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure 12. Swimmer plot showing overall patient survival from initial cancer diagnosis.
Figure S2 from Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers
Authors: Nevler Avinoam , Muller Alexander J. , Sutanto-Ward Erika , DuHadaway James B. , Nagatomo Kei , Londin Eric , O'Hayer Kevin , Cozzitorto Joseph A. , Lavu Harish , Yeo Theresa P. , Curtis Mark , Villatoro Tatiana , Leiby Benjamin E. , Mandik-Nayak Laura , Winter Jordan M. , Yeo Charles J. , Prendergast George C. , Brody Jonathan R.
Published: April 2023

Bar graphs (black and white line and dot drawing)
Supplementary Data from Phase I Trial of Inducible Caspase 9 T Cells in Adult Stem Cell Transplant Demonstrates Massive Clonotypic Proliferative Potential and Long-term Persistence of Transgenic T Cells
Authors: Zhang Ping , Raju Jyothy , Ullah Md Ashik , Au Raymond , Varelias Antiopi , Gartlan Kate H. , Olver Stuart D. , Samson Luke D. , Sturgeon Elise , Zomerdijk Nienke , Avery Judy , Gargett Tessa , Brown Michael P. , Coin Lachlan J. , Ganesamoorthy Devika , Hutchins Cheryl , Pratt Gary R. , Kennedy Glen A. , Morton A. James , Curley Cameron I. , Hill Geoffrey R. , Tey Siok-Keen
Published: April 2023

Supplemental Material
Move S5 from Measurement of Tumor Antioxidant Capacity and Prediction of Chemotherapy Resistance in Preclinical Models of Ovarian Cancer by Positron Emission Tomography
Authors: Greenwood Hannah E. , McCormick Patrick N. , Gendron Thibault , Glaser Matthias , Pereira Raul , Maddocks Oliver D. K. , Sander Kerstin , Zhang Tong , Koglin Norman , Lythgoe Mark F. , Årstad Erik , Hochhauser Daniel , Witney Timothy H.
Published: April 2023

Video 5
Move S4 from Measurement of Tumor Antioxidant Capacity and Prediction of Chemotherapy Resistance in Preclinical Models of Ovarian Cancer by Positron Emission Tomography
Authors: Greenwood Hannah E. , McCormick Patrick N. , Gendron Thibault , Glaser Matthias , Pereira Raul , Maddocks Oliver D. K. , Sander Kerstin , Zhang Tong , Koglin Norman , Lythgoe Mark F. , Årstad Erik , Hochhauser Daniel , Witney Timothy H.
Published: April 2023

Video 4
Supplementary Figure 1 from Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion
Authors: Ryu Daeun , Kim Seok Jin , Hong Yourae , Jo Areum , Kim Nayoung , Kim Hee-Jin , Lee Hae-Ock , Kim Kihyun , Park Woong-Yang
Published: April 2023

Visualization of immune cell landscape for multiple myeloma and healthy bone marrow.
Supplementary Data from Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer
Authors: Saleh Anthony D. , Cheng Hui , Martin Scott E. , Si Han , Ormanoglu Pinar , Carlson Sophie , Clavijo Paul E. , Yang Xinping , Das Rita , Cornelius Shaleeka , Couper Jamie , Chepeha Douglas , Danilova Ludmila , Harris Thomas M. , Prystowsky Michael B. , Childs Geoffrey J. , Smith Richard V. , Robertson A. Gordon , Jones Steven J. M. , Cherniack Andrew D. , Kim Sang S. , Rait Antonina , Pirollo Kathleen F. , Chang Esther H. , Chen Zhong , Van Waes Carter
Published: April 2023

Supplementary Methods, References, Figure legends, Table S2
Supp Table S1, S3-8 from Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer
Authors: Saleh Anthony D. , Cheng Hui , Martin Scott E. , Si Han , Ormanoglu Pinar , Carlson Sophie , Clavijo Paul E. , Yang Xinping , Das Rita , Cornelius Shaleeka , Couper Jamie , Chepeha Douglas , Danilova Ludmila , Harris Thomas M. , Prystowsky Michael B. , Childs Geoffrey J. , Smith Richard V. , Robertson A. Gordon , Jones Steven J. M. , Cherniack Andrew D. , Kim Sang S. , Rait Antonina , Pirollo Kathleen F. , Chang Esther H. , Chen Zhong , Van Waes Carter
Published: April 2023

Supplementary Table S1, S3-8
Figure S4 from Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
Authors: Corella Alexandra N. , Cabiliza Ordonio Ma Victoria Andrea , Coleman Ilsa , Lucas Jared M. , Kaipainen Arja , Nguyen Holly M. , Sondheim Daniel , Brown Lisha G. , True Lawrence D. , Lee John K. , MacPherson David , Nghiem Paul , Gulati Roman , Morrissey Colm , Corey Eva , Nelson Peter S.
Published: April 2023

Figure S4. Assessments of Wee1 expression and anti-Wee1 activity.
Figure S3 from Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
Authors: Corella Alexandra N. , Cabiliza Ordonio Ma Victoria Andrea , Coleman Ilsa , Lucas Jared M. , Kaipainen Arja , Nguyen Holly M. , Sondheim Daniel , Brown Lisha G. , True Lawrence D. , Lee John K. , MacPherson David , Nghiem Paul , Gulati Roman , Morrissey Colm , Corey Eva , Nelson Peter S.
Published: April 2023

Figure S3. Effects of targeting BCL2 and expression of BCL2 family members in prostate cancer cell lines and PDX models.
Supplementary Figure Legends and Data Tables from Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer
Authors: Nouri Mannan , Massah Shabnam , Caradec Josselin , Lubik Amy A. , Li Na , Truong Sarah , Lee Ahn R. , Fazli Ladan , Ramnarine Varune R. , Lovnicki Jessica M. , Moore Jackson , Wang Mike , Foo Jane , Gleave Martin E. , Hollier Brett G. , Nelson Colleen , Collins Colin , Dong Xuesen , Buttyan Ralph
Published: April 2023

Supplementary Figure Legends and Data Table containing developmental reprogramming 59-Gene commonly regulated gene list.
Supplementary Table S4. Literature Review - Efficacy Outcomes by MRD Log-Group for B-cell ALL CR1 using End-Of-Induction MRD Measurements from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
Authors: Jen Emily Y. , Xu Qing , Schetter Aaron , Przepiorka Donna , Shen Yuan Li , Roscoe Donna , Sridhara Rajeshwari , Deisseroth Albert , Philip Reena , Farrell Ann T. , Pazdur Richard
Published: April 2023

Literature review - efficacy by log-group MRD
Supplementary Table S2. Safety Population - Common ({greater than or equal to} 10%) Adverse Reactions from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
Authors: Jen Emily Y. , Xu Qing , Schetter Aaron , Przepiorka Donna , Shen Yuan Li , Roscoe Donna , Sridhara Rajeshwari , Deisseroth Albert , Philip Reena , Farrell Ann T. , Pazdur Richard
Published: April 2023

Common AR
Figure S1, Figure S2, Table S1, Table S2. from Submucosal Saline Injection Followed by Endoscopic Ultrasound versus Endoscopic Ultrasound Only for Distinguishing between T1a and T1b Esophageal Cancer
Authors: He Long-Jun , Xie Chuanbo , Wang Zi-Xian , Li Yin , Xiao Yi-Tai , Gao Xiao-Yan , Shan Hong-Bo , Luo Lin-Na , Chen Li-Ming , Luo Guang-Yu , Yang Ping , Zeng Shuo-Chun , Xu Guo-Liang , Li Jian-Jun
Published: April 2023

Figure S1, Schematic diagrams of the esophageal wall after submucosal saline injection (SSI); Figure S2, Receiver operating characteristic curves of submucosal saline injection followed by endoscopic ultrasound and endoscopic ultrasound only for distinguishing T1a and T1b esophageal squamous cell carcinoma; Table S1, The diagnostic performance of submucosal saline injection followed by EUS (SSI+EUS) and endoscopic ultrasound (EUS) in sub-staging T1 stage esophageal squamous cell carcinoma; Table S2, The diagnostic performance of submucosal saline injection followed by EUS (SSI+EUS) and endoscopic ultrasound (EUS) in sub-staging T1 stage esophageal squamous cell carcinoma among patients without postoperative atypical hyperplasia.
Supplementary Figures from Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer
Authors: Xiao Yi , Ma Ding , Zhao Shen , Suo Chen , Shi Jinxiu , Xue Meng-Zhu , Ruan Miao , Wang Hai , Zhao Jingjing , Li Qin , Wang Peng , Shi Leming , Yang Wen-Tao , Huang Wei , Hu Xin , Yu Ke-Da , Huang Shenglin , Bertucci François , Jiang Yi-Zhou , Shao Zhi-Ming
Published: April 2023

Supplementary Figure 1. Workflow of our research. Supplementary Figure 2. Estimation of the optimal clustering numbers of triple-negative breast cancer microenvironment phenotypes. Supplementary Figure 3. Validation of microenvironment phenotypes clustering in METABRIC cohort. Supplementary Figure 4. Validation of microenvironment phenotypes clustering in TCGA cohort. Supplementary Figure 5. Comparison of potential molecules involved in the initiation of innate immunity among microenvironment clusters in FUSCCTNBC cohort. Supplementary Figure 6. SNV and indel neoantigen load of the three microenvironment clusters in triple-negative breast cancer. Supplementary Figure 7. Chromosome instability of the three microenvironment clusters in triple-negative breast cancer. Supplementary Figure 8. Cancer testis antigen landscape of triple-negative breast cancer. Supplementary Figure 9. Gene set enrichment analysis of enriched pathways in each cluster. Supplementary Figure 10. Batch effect evaluation after "Combat" of RNA-seq and HTA microarray datasets. Supplementary Figure 11. Process and validation of mRNA clustering.
Supplementary Material from Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
Authors: Hong David S. , LoRusso Patricia , Hamid Omid , Janku Filip , Kittaneh Muaiad , Catenacci Daniel V.T. , Chan Emily , Bekaii-Saab Tanios , Gadgeel Shirish M. , Loberg Robert D. , Amore Benny M. , Hwang Yuying C. , Tang Rui , Ngarmchamnanrith Gataree , Kwak Eunice L.
Published: April 2023

Supplementary Material
Figure S3 from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma
Authors: Hall Peter E. , Lewis Rachel , Syed Nelofer , Shaffer Richard , Evanson Jane , Ellis Stephen , Williams Matthew , Feng Xiaoxing , Johnston Amanda , Thomson Jim A. , Harris Fiona P. , Jena Raj , Matys Tomasz , Jefferies Sarah , Smith Kate , Wu Bor-Wen , Bomalaski John S. , Crook Timothy , O'Neill Kevin , Paraskevopoulos Dimitris , Khadeir Ramsay S. , Sheaff Michael , Pacey Simon , Plowman Piers N. , Szlosarek Peter W.
Published: April 2023

Effects of ADI-PEG20 on the folate pathway
Supplementary Data from A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
Authors: Turner Nicholas C. , Telli Melinda L. , Rugo Hope S. , Mailliez Audrey , Ettl Johannes , Grischke Eva-Maria , Mina Lida A. , Balmaña Judith , Fasching Peter A. , Hurvitz Sara A. , Wardley Andrew M. , Chappey Colombe , Hannah Alison L. , Robson Mark E.
Published: April 2023

This supplementary appendix contains a listing of all the investigators involved in the ABRAZO study. It also includes information regarding key eligibility criteria for the study. Finally, a figure showing progression-free survival and overall survival by cohort is given.
Figure S5 from Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine
Authors: Wang Sabrina Z. , Poore Brad , Alt Jesse , Price Antoinette , Allen Sariah J. , Hanaford Allison R. , Kaur Harpreet , Orr Brent A. , Slusher Barbara S. , Eberhart Charles G. , Raabe Eric H. , Rubens Jeffrey A.
Published: April 2023

ANNEXIN V assay after DON/Carboplatin treatments
Figure S3 from Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine
Authors: Wang Sabrina Z. , Poore Brad , Alt Jesse , Price Antoinette , Allen Sariah J. , Hanaford Allison R. , Kaur Harpreet , Orr Brent A. , Slusher Barbara S. , Eberhart Charles G. , Raabe Eric H. , Rubens Jeffrey A.
Published: April 2023

Response of high and low MYC cell lines to DON treatment
Table from Detection of NRG1 Gene Fusions in Solid Tumors
Authors: Jonna Sushma , Feldman Rebecca A. , Swensen Jeffrey , Gatalica Zoran , Korn Wolfgang M. , Borghaei Hossein , Ma Patrick C. , Nieva Jorge J. , Spira Alexander I. , Vanderwalde Ari M. , Wozniak Antoinette J. , Kim Edward S. , Liu Stephen V.
Published: April 2023

Table S1. Descriptions of NRG1 Fusions Identified. *Novel fusion. Abbreviations: NSCLC, non-small cell lung cancer; PDAC, pancreatic ductal adenocarcinoma; GBC, gallbladder cancer (cholangiocarcinoma); CRC, colorectal cancer. RCC, renal cell carcinoma; NET, neuroendocrine tumor.
Figure S2 from Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine
Authors: Wang Sabrina Z. , Poore Brad , Alt Jesse , Price Antoinette , Allen Sariah J. , Hanaford Allison R. , Kaur Harpreet , Orr Brent A. , Slusher Barbara S. , Eberhart Charles G. , Raabe Eric H. , Rubens Jeffrey A.
Published: April 2023

Growth of cell lines in glutamine-free media
Figure S3 from Detection of NRG1 Gene Fusions in Solid Tumors
Authors: Jonna Sushma , Feldman Rebecca A. , Swensen Jeffrey , Gatalica Zoran , Korn Wolfgang M. , Borghaei Hossein , Ma Patrick C. , Nieva Jorge J. , Spira Alexander I. , Vanderwalde Ari M. , Wozniak Antoinette J. , Kim Edward S. , Liu Stephen V.
Published: April 2023

Figure S3 from Detection of NRG1 Gene Fusions in Solid Tumors
Supplementary Data from Neutrophil Extracellular Traps Induced by IL8 Promote Diffuse Large B-cell Lymphoma Progression via the TLR9 Signaling
Authors: Nie Man , Yang Linbin , Bi Xiwen , Wang Yu , Sun Peng , Yang Hang , Liu Panpan , Li Zhiming , Xia Yi , Jiang Wenqi
Published: April 2023

It includes supplementary methods, 7 figures and 10 tables.
Table S4 from The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response
Authors: Law Henry C.-H. , Lagundžin Dragana , Clement Emalie J. , Qiao Fangfang , Wagner Zachary S. , Krieger Kimiko L. , Costanzo-Garvey Diane , Caffrey Thomas C. , Grem Jean L. , DiMaio Dominick J. , Grandgenett Paul M. , Cook Leah M. , Fisher Kurt W. , Yu Fang , Hollingsworth Michael A. , Woods Nicholas T.
Published: April 2023

Table S4: The total list of peptides identified.
Figures S1-S5 from The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response
Authors: Law Henry C.-H. , Lagundžin Dragana , Clement Emalie J. , Qiao Fangfang , Wagner Zachary S. , Krieger Kimiko L. , Costanzo-Garvey Diane , Caffrey Thomas C. , Grem Jean L. , DiMaio Dominick J. , Grandgenett Paul M. , Cook Leah M. , Fisher Kurt W. , Yu Fang , Hollingsworth Michael A. , Woods Nicholas T.
Published: April 2023

Figure S1: The complete gene ontology annotation on the Spatial Analysis for Functional Enrichment (SAFE) network for proteins identified by mass spectrometry. Figure S2: Proteomics distinguishes pancreatic cancer metastases in the liver from tumor adjacent liver tissue. Figure S3: The residual variance versus the numbers of protein and sample clusters as defined by the PCA hierarchical clustering model, and the distribution of proteomic subtypes across the 7 batches of PDAC samples. Figure S4: Comparison of proteomic PDAC subtype classification in relation to previously established transcriptomic classification systems. Figure S5: The PLS-DA score plot of the proteomic subtype as determined in the liver metastases proteome versus the primary tumor proteome.
Supplementary Figure 6 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
Authors: Yan Dongqing , Pomicter Anthony D. , Tantravahi Srinivas , Mason Clinton C. , Senina Anna V. , Ahmann Jonathan M. , Wang Qiang , Than Hein , Patel Ami B. , Heaton William L. , Eiring Anna M. , Clair Phillip M. , Gantz Kevin C. , Redwine Hannah M. , Swierczek Sabina I. , Halverson Brayden J. , Baloglu Erkan , Shacham Sharon , Khorashad Jamshid S. , Kelley Todd W. , Salama Mohamed E. , Miles Rodney R. , Boucher Kenneth M. , Prchal Josef T. , O'Hare Thomas , Deininger Michael W.
Published: April 2023

Supplementary Figure 6
Supplementary Figure 5 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
Authors: Yan Dongqing , Pomicter Anthony D. , Tantravahi Srinivas , Mason Clinton C. , Senina Anna V. , Ahmann Jonathan M. , Wang Qiang , Than Hein , Patel Ami B. , Heaton William L. , Eiring Anna M. , Clair Phillip M. , Gantz Kevin C. , Redwine Hannah M. , Swierczek Sabina I. , Halverson Brayden J. , Baloglu Erkan , Shacham Sharon , Khorashad Jamshid S. , Kelley Todd W. , Salama Mohamed E. , Miles Rodney R. , Boucher Kenneth M. , Prchal Josef T. , O'Hare Thomas , Deininger Michael W.
Published: April 2023

Supplementary Figure 5
Supplementary Figure 5 from Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy
Authors: Karches Clara H. , Benmebarek Mohamed-Reda , Schmidbauer Moritz L. , Kurzay Mathias , Klaus Richard , Geiger Martina , Rataj Felicitas , Cadilha Bruno L. , Lesch Stefanie , Heise Constanze , Murr Ramona , vom Berg Johannes , Jastroch Martin , Lamp Daniel , Ding Jian , Duewell Peter , Niederfellner Gerhard , Sustmann Claudio , Endres Stefan , Klein Christian , Kobold Sebastian
Published: April 2023

Supplementary Figure 5: Effect of pre-activated SAR T cells on hepatocellular carcinoma and glioblastoma cellsâ€¨
Supplementary Figure 3 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
Authors: Yan Dongqing , Pomicter Anthony D. , Tantravahi Srinivas , Mason Clinton C. , Senina Anna V. , Ahmann Jonathan M. , Wang Qiang , Than Hein , Patel Ami B. , Heaton William L. , Eiring Anna M. , Clair Phillip M. , Gantz Kevin C. , Redwine Hannah M. , Swierczek Sabina I. , Halverson Brayden J. , Baloglu Erkan , Shacham Sharon , Khorashad Jamshid S. , Kelley Todd W. , Salama Mohamed E. , Miles Rodney R. , Boucher Kenneth M. , Prchal Josef T. , O'Hare Thomas , Deininger Michael W.
Published: April 2023

Supplementary Figure 3
Supplementary Figure 4 from Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy
Authors: Karches Clara H. , Benmebarek Mohamed-Reda , Schmidbauer Moritz L. , Kurzay Mathias , Klaus Richard , Geiger Martina , Rataj Felicitas , Cadilha Bruno L. , Lesch Stefanie , Heise Constanze , Murr Ramona , vom Berg Johannes , Jastroch Martin , Lamp Daniel , Ding Jian , Duewell Peter , Niederfellner Gerhard , Sustmann Claudio , Endres Stefan , Klein Christian , Kobold Sebastian
Published: April 2023

Supplementary Figure 4: Human SAR T cells are specifically stimulated by anti-human mesothelin x anti-EGFRv3 2 + 1 BiAb and redirect lysis to mesothelin+ target cells in vitro and in vivo
Supplementary Video S6 from MAP9 Loss Triggers Chromosomal Instability, Initiates Colorectal Tumorigenesis, and Is Associated with Poor Survival of Patients with Colorectal Cancer
Authors: Wang Shiyan , Huang Junzhe , Li Chuangen , Zhao Liuyang , Wong Chi Chun , Zhai Jianning , Zhou Yunfei , Deng Wen , Zeng Yong , Gao Shanshan , Zhang Yanquan , Wang Guoping , Guan Xin Yuan , Wei Hong , Wong Sunny H. , He Housheng H. , Shay Jerry W. , Yu Jun
Published: April 2023

Supplementary Video S6
Table S1 from First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
Authors: Somaiah Neeta , Block Matthew S. , Kim Joseph W. , Shapiro Geoffrey I. , Do Khanh T. , Hwu Patrick , Eder Joseph P. , Jones Robin L. , Lu Hailing , ter Meulen Jan H. , Bohac Chet , Chen Michael , Hsu Frank J. , Gnjatic Sacha , Pollack Seth M.
Published: April 2023

Table S1 shows maximum eligible tumor burden by tumor type.
Supplementary Video S1 from MAP9 Loss Triggers Chromosomal Instability, Initiates Colorectal Tumorigenesis, and Is Associated with Poor Survival of Patients with Colorectal Cancer
Authors: Wang Shiyan , Huang Junzhe , Li Chuangen , Zhao Liuyang , Wong Chi Chun , Zhai Jianning , Zhou Yunfei , Deng Wen , Zeng Yong , Gao Shanshan , Zhang Yanquan , Wang Guoping , Guan Xin Yuan , Wei Hong , Wong Sunny H. , He Housheng H. , Shay Jerry W. , Yu Jun
Published: April 2023

Supplementary Video S1
Figure S3 from Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response
Authors: Payen Thomas , Oberstein Paul E. , Saharkhiz Niloufar , Palermo Carmine F. , Sastra Stephen A. , Han Yang , Nabavizadeh Alireza , Sagalovskiy Irina R. , Orelli Barbara , Rosario Vilma , Desrouilleres Deborah , Remotti Helen , Kluger Michael D. , Schrope Beth A. , Chabot John A. , Iuga Alina C. , Konofagou Elisa E. , Olive Kenneth P.
Published: April 2023

Figure S3
Supplementary Table S5 from MAP9 Loss Triggers Chromosomal Instability, Initiates Colorectal Tumorigenesis, and Is Associated with Poor Survival of Patients with Colorectal Cancer
Authors: Wang Shiyan , Huang Junzhe , Li Chuangen , Zhao Liuyang , Wong Chi Chun , Zhai Jianning , Zhou Yunfei , Deng Wen , Zeng Yong , Gao Shanshan , Zhang Yanquan , Wang Guoping , Guan Xin Yuan , Wei Hong , Wong Sunny H. , He Housheng H. , Shay Jerry W. , Yu Jun
Published: April 2023

Supplementary Table S5
Figure S2 from Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response
Authors: Payen Thomas , Oberstein Paul E. , Saharkhiz Niloufar , Palermo Carmine F. , Sastra Stephen A. , Han Yang , Nabavizadeh Alireza , Sagalovskiy Irina R. , Orelli Barbara , Rosario Vilma , Desrouilleres Deborah , Remotti Helen , Kluger Michael D. , Schrope Beth A. , Chabot John A. , Iuga Alina C. , Konofagou Elisa E. , Olive Kenneth P.
Published: April 2023

Figure S2
Supplementary figure from Oncolytic HSV–Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition
Authors: Otani Yoshihiro , Yoo Ji Young , Chao Samantha , Liu Joseph , Jaime-Ramirez Alena Cristina , Lee Tae Jin , Hurwitz Brian , Yan Yuanqing , Dai Hongsheng , Glorioso Joseph C. , Caligiuri Michael A. , Yu Jianhua , Kaur Balveen
Published: April 2023

Supplementary Figures S1-S8
Supplementary Fig. S1-S8 from Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients
Authors: Kobayashi Masato , Chung Jin-Sung , Beg Muhammad , Arriaga Yull , Verma Udit , Courtney Kevin , Mansour John , Haley Barbara , Khan Saad , Horiuchi Yutaka , Ramani Vijay , Harker David , Gopal Purva , Araghizadeh Farshid , Cruz Ponciano D. , Ariizumi Kiyoshi
Published: April 2023

Supplementary Fig. S1. Early stages CRC patients expressed very low DC-HIL expression on MDSCs. Supplementary Fig. S2. No effect of anti-CD14 mAb on T cell suppressor function of MDSCs. Supplementary Fig. S3. DC-HILneg MC38 and CT26 mouse colon cancer cell lines exhibit high response to anti-DC-HIL treatment. Supplementary Fig. S4. MDSCs in spleen and draining lymph nodes did not express DC-HIL. Supplementary Fig. S5. Combination treatment of anti-DC-HIL/anti-PDL1 mAb did not produce synergistic anti-tumor effects to MC38 colon cancer. Supplementary Fig. S6. Changes in health conditions of mice treated with anti-DC-HIL mAb. Supplementary Fig. S7. Representative FACS data showing frequency of immune cells in the tumor microenvironment of mice treated with mAb. Supplementary Fig. S8. Blood granulocytic MDSC of CRC patients expressed low-levels of DC-HIL and were not immunosuppressive in ex vivo cultures.
legends from Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity
Authors: Baro Marta , Lopez Sambrooks Cecilia , Quijano Amanda , Saltzman W. Mark , Contessa Joseph
Published: April 2023

Supplementary figures legends
Table S5 from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
Authors: Toledo Rodrigo A. , Garralda Elena , Mitsi Maria , Pons Tirso , Monsech Jorge , Vega Estela , Otero Álvaro , Albarran Maria I. , Baños Natalia , Durán Yolanda , Bonilla Victoria , Sarno Francesca , Camacho-Artacho Marta , Sanchez-Perez Tania , Perea Sofia , Álvarez Rafael , De Martino Alba , Lietha Daniel , Blanco-Aparicio Carmen , Cubillo Antonio , Domínguez Orlando , Martínez-Torrecuadrada Jorge L. , Hidalgo Manuel
Published: April 2023

Table S5: List of KDR/VEGFR2 somatic mutations from the Cosmic, TCGA, GENIE and PCA-WGS databases.
Table S4 from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
Authors: Toledo Rodrigo A. , Garralda Elena , Mitsi Maria , Pons Tirso , Monsech Jorge , Vega Estela , Otero Álvaro , Albarran Maria I. , Baños Natalia , Durán Yolanda , Bonilla Victoria , Sarno Francesca , Camacho-Artacho Marta , Sanchez-Perez Tania , Perea Sofia , Álvarez Rafael , De Martino Alba , Lietha Daniel , Blanco-Aparicio Carmen , Cubillo Antonio , Domínguez Orlando , Martínez-Torrecuadrada Jorge L. , Hidalgo Manuel
Published: April 2023

Table S4: Primers used for site-directed mutagenesis. The mutated nucleotides are indicated in bold and underlined in each mutant.
Supplementary figure 1 from Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity
Authors: Baro Marta , Lopez Sambrooks Cecilia , Quijano Amanda , Saltzman W. Mark , Contessa Joseph
Published: April 2023

Dose response of NGI-1, temozolomide and etoposide in glioma cell lines
Table S2 from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
Authors: Toledo Rodrigo A. , Garralda Elena , Mitsi Maria , Pons Tirso , Monsech Jorge , Vega Estela , Otero Álvaro , Albarran Maria I. , Baños Natalia , Durán Yolanda , Bonilla Victoria , Sarno Francesca , Camacho-Artacho Marta , Sanchez-Perez Tania , Perea Sofia , Álvarez Rafael , De Martino Alba , Lietha Daniel , Blanco-Aparicio Carmen , Cubillo Antonio , Domínguez Orlando , Martínez-Torrecuadrada Jorge L. , Hidalgo Manuel
Published: April 2023

Table S2: Custom primers and probes designed based on the Thermofisher online design tool for TaqManÃ,Â® genotyping assay for KDR c.2518C>T (VEGFR2 p.L840L). TaqManÃ,Â® MGB (minor groove binder) probes incorporate a 5' reporter (VIC or FAM) and a 3' nonfluorescent quencher (NFQ).
Online Methods from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
Authors: Toledo Rodrigo A. , Garralda Elena , Mitsi Maria , Pons Tirso , Monsech Jorge , Vega Estela , Otero Álvaro , Albarran Maria I. , Baños Natalia , Durán Yolanda , Bonilla Victoria , Sarno Francesca , Camacho-Artacho Marta , Sanchez-Perez Tania , Perea Sofia , Álvarez Rafael , De Martino Alba , Lietha Daniel , Blanco-Aparicio Carmen , Cubillo Antonio , Domínguez Orlando , Martínez-Torrecuadrada Jorge L. , Hidalgo Manuel
Published: April 2023

Detailed methods
Figure S6 from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
Authors: Toledo Rodrigo A. , Garralda Elena , Mitsi Maria , Pons Tirso , Monsech Jorge , Vega Estela , Otero Álvaro , Albarran Maria I. , Baños Natalia , Durán Yolanda , Bonilla Victoria , Sarno Francesca , Camacho-Artacho Marta , Sanchez-Perez Tania , Perea Sofia , Álvarez Rafael , De Martino Alba , Lietha Daniel , Blanco-Aparicio Carmen , Cubillo Antonio , Domínguez Orlando , Martínez-Torrecuadrada Jorge L. , Hidalgo Manuel
Published: April 2023

Figure S6: Assessment of the expression of phosphorylated ERK (p-ERK) in the WT and L840F VEGFR2 PDX Avatar models by immunohistochemistry (A), confocal microscopy (B), and immunoblotting (C). The MAPK pathway was activated in the L840F VEGFR2 mutant model and was not decreased following treatment with TKIs.
Supplementary Information from Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma
Authors: Chen Gregory M. , Kannan Lavanya , Geistlinger Ludwig , Kofia Victor , Safikhani Zhaleh , Gendoo Deena M.A. , Parmigiani Giovanni , Birrer Michael , Haibe-Kains Benjamin , Waldron Levi
Published: April 2023

Reproduction of all main results.
Supplementary Tables S1-S7 from An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer
Authors: Brave Michael , Weinstock Chana , Brewer Jamie R. , Chi Dow-Chung , Suzman Daniel L. , Cheng Joyce , Zhang Lijun , Sridhara Rajeshwari , Ibrahim Amna , Kluetz Paul G. , Pazdur Richard , Beaver Julia A.
Published: April 2023

Supplementary Tables S1-S7
Figure S3 from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
Authors: Toledo Rodrigo A. , Garralda Elena , Mitsi Maria , Pons Tirso , Monsech Jorge , Vega Estela , Otero Álvaro , Albarran Maria I. , Baños Natalia , Durán Yolanda , Bonilla Victoria , Sarno Francesca , Camacho-Artacho Marta , Sanchez-Perez Tania , Perea Sofia , Álvarez Rafael , De Martino Alba , Lietha Daniel , Blanco-Aparicio Carmen , Cubillo Antonio , Domínguez Orlando , Martínez-Torrecuadrada Jorge L. , Hidalgo Manuel
Published: April 2023

Figure S3: Analyses of interactions between tyrosine kinase receptors and kinase inhibitors, performed with LigProt.
Supplementary figure 1 from Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors
Authors: Atrafi Florence , van Eerden Ruben A.G. , van Hylckama Vlieg Marte A.M , Oomen-de Hoop Esther , de Bruijn Peter , Lolkema Martijn P. , Moelker Adriaan , Rijcken Cristianne J. , Hanssen Rob , Sparreboom Alex , Eskens Ferry A.L.M. , Mathijssen Ron H.J. , Koolen Stijn L.W.
Published: April 2023

Supplementary figure 1
Tables S7-S8 from Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma
Authors: Amin-Mansour Ali , George Suzanne , Sioletic Stefano , Carter Scott L. , Rosenberg Mara , Taylor-Weiner Amaro , Stewart Chip , Chevalier Aaron , Seepo Sara , Tracy Adam , Getz Gad , Hornick Jason L. , Nucci Marisa R. , Quade Bradley , Demetri George D. , Raut Chandrajit P. , Garraway Levi A. , Van Allen Eliezer M. , Wagner Andrew J.
Published: April 2023

Supplementary Tables 7 and 8
Supplementary Figure 1 from A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer
Authors: Oza Amit M. , Estevez-Diz Maria , Grischke Eva-Maria , Hall Marcia , Marmé Frederik , Provencher Diane , Uyar Denise , Weberpals Johanne I. , Wenham Robert M. , Laing Naomi , Tracy Michael , Freshwater Tomoko , Lee Mark A. , Liu Ji , Qiu Jingjun , Rose Shelonitda , Rubin Eric H. , Moore Kathleen
Published: April 2023

Supplementary Figure 1
Supplementary Figure S2 from The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Authors: Pilla Reddy Venkatesh , Anjum Rana , Grondine Michael , Smith Aaron , Bhavsar Deepa , Barry Evan , Guichard Sylvie M. , Shao Wenlin , Kettle Jason G. , Brown Crystal , Banks Erica , Jones Rhys D.O.
Published: April 2023

PK model fit for AZD3229 dosed orally in the mouse
Tables S1-S4 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel
Authors: Faramand Rawan , Jain Michael , Staedtke Verena , Kotani Hiroshi , Bai Renyuan , Reid Kayla , Lee Sae Bom , Spitler Kristen , Wang Xuefeng , Cao Biwei , Pinilla Javier , Lazaryan Aleksander , Khimani Farhad , Shah Bijal , Chavez Julio C. , Nishihori Taiga , Mishra Asmita , Mullinax John , Gonzalez Ricardo , Hussaini Mohammad , Dam Marian , Brandjes Brigett D. , Bachmeier Christina A. , Anasetti Claudio , Locke Frederick L. , Davila Marco L.
Published: April 2023

Supplementary tables and figure legends
Supplementary Data Legends from Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation
Authors: Liu Chao , Sadat Sayed H. , Ebisumoto Koji , Sakai Akihiro , Panuganti Bharat A. , Ren Shuling , Goto Yusuke , Haft Sunny , Fukusumi Takahito , Ando Mizuo , Saito Yuki , Guo Theresa , Tamayo Pablo , Yeerna Huwate , Kim William , Hubbard Jacqueline , Sharabi Andrew B. , Gutkind J. Silvio , Califano Joseph A.
Published: April 2023

Supplementary Data Legends
Figure S5 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor
Authors: Zhang Jiajun , Liu Weihai , Zou Changye , Zhao Zhiqiang , Lai Yuanying , Shi Zhi , Xie Xianbiao , Huang Gang , Wang Yongqian , Zhang Xuelin , Fan Zepei , Su Qiao , Yin Junqiang , Shen Jingnan
Published: April 2023

Specificity and efficiency of RT-qPCR primers.
Figure S4 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor
Authors: Zhang Jiajun , Liu Weihai , Zou Changye , Zhao Zhiqiang , Lai Yuanying , Shi Zhi , Xie Xianbiao , Huang Gang , Wang Yongqian , Zhang Xuelin , Fan Zepei , Su Qiao , Yin Junqiang , Shen Jingnan
Published: April 2023

H&E staining of paraffin embedded sections of the heart, liver, spleen, lung and kidney.
Supplementary Methods from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Authors: Narasimhan Vignesh , Wright Josephine A. , Churchill Michael , Wang Tongtong , Rosati Rachele , Lannagan Tamsin R.M. , Vrbanac Laura , Richardson Anne B. , Kobayashi Hiroki , Price Timothy , Tye Gayle X.Y. , Marker Julie , Hewett Peter J. , Flood Michael P. , Pereira Shalini , Whitney G. Adam , Michael Michael , Tie Jeanne , Mukherjee Siddhartha , Grandori Carla , Heriot Alexander G. , Worthley Daniel L. , Ramsay Robert G. , Woods Susan L.
Published: April 2023

Supplementary Methods